Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy

Next Previous
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 21 Oct 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alirocumab (Primary) ; Atorvastatin; Rosuvastatin; Simvastatin
  • Indications Atherosclerosis; Cardiovascular disorders; Hypercholesterolaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms ODYSSEY-Combo-I
  • Sponsors Sanofi

Most Recent Events

  • 17 Oct 2021 Results of Meta-Analysis from eight randomized, double-blind, placebo-controlled studies assessing Clinical Outcomes of PCSK9 Modulators in Patients with Established ASCVD published in the Pharmacotherapy
  • 05 Sep 2018 Results of pooled data from 14 trials, were published in the Diabetic Medicine.
  • 01 Jun 2018 Results of a pooled analysis of 5 studies (LONG TERM, HIGH FH, FH I, FH II and COMBO) assessing the safety and efficacy of Alirocumab, published in the Diabetes Therapy

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top